-
公开(公告)号：US5902785A
公开(公告)日：1999-05-11
申请号：US646193
申请日：1996-05-07
CPC分类号： A61L27/227 , A61K38/1875 , C07K14/51
摘要： Compositions of proteins with cartilaginous tissue inducing and maintenance activity are disclosed. The compositions are useful in the treatment of osteoarthritis, cartilage defects and in related tissue repair.
摘要翻译： 公开了具有软骨组织诱导和维持活性的蛋白质组合物。 组合物可用于治疗骨关节炎，软骨缺损和相关组织修复。
-
公开(公告)号：US06689599B1
公开(公告)日：2004-02-10
申请号：US09981953
申请日：2001-10-18
IPC分类号： C12N964
CPC分类号： C12N9/6421
摘要： Aggrecanase proteins and the nucleotides sequences encoding them as well as processes for producing them are disclosed. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
摘要翻译： 公开了聚集蛋白聚糖蛋白和编码它们的核苷酸序列以及其生产方法。 还公开了开发聚蛋白聚糖酶的抑制剂的方法和用于治疗以聚集蛋白聚糖降解为特征的病症的酶的抗体的方法。
-
公开(公告)号：US20080311113A1
公开(公告)日：2008-12-18
申请号：US12123990
申请日：2008-05-20
IPC分类号： A61K39/395 , G01N33/566 , G01N33/53 , A61P3/00 , A61P1/00 , A61P9/00 , A61P25/00 , A61P21/00 , A61P35/04
CPC分类号： C07D213/30 , A61K31/4188 , A61K31/424 , A61K31/429 , C07C311/29 , C07C311/46 , C07C2601/08 , C07C2602/10 , C07D213/64 , C07D213/643 , C07D215/14 , C07D215/227 , C07D215/233 , C07D217/18 , C07D235/12 , C07D239/34 , C07D239/60 , C07D261/14 , C07D263/22 , C07D263/58 , C07D277/64 , C07D277/68 , C07D295/096 , C07D295/192 , C07D307/79 , C07D307/80 , C07D307/82 , C07D307/84 , C07D319/18 , C07D321/10 , C07D333/20 , C07D333/36 , C07D333/66
摘要： The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.
摘要翻译： 本发明涉及治疗ADAMTS-5相关疾病，特别是骨关节炎的方法，其包括将能够将ADMATS-5活性调节至患有该疾病的受试者的药剂。 该试剂优选为联芳基磺酰胺化合物。 本发明部分地基于以下发现：与WT动物相比，不表达功能性ADAMTS-5的转基因动物在诱导骨关节炎之后表现出降低骨关节炎的程度。 此外，ADAMTS-5转基因动物与WT动物相比降低了关节组织中的聚集蛋白聚糖蛋白聚糖酶活性。 这些动物是ADAMTS-5相关疾病的良好模型，并且用于筛选可用于治疗和/或预防这些疾病的药物。 没有其他动物模型，其中单个基因的活性的缺失能够消除骨关节炎的过程。 因此，这些动物还显示可以通过向受试者施用ADAMTS-5抑制剂，特别是能够抑制ADAMTS-5的聚集蛋白聚糖酶活性的试剂来预防和/或治疗骨关节炎。
-
公开(公告)号：US07390833B2
公开(公告)日：2008-06-24
申请号：US10983981
申请日：2004-11-08
IPC分类号： A01N41/02 , A01N37/34 , A01N37/30 , A01N37/12 , A01N37/44 , A61K31/275 , A61K31/205 , A61K31/195 , A61K31/255
CPC分类号： C07D213/30 , A61K31/4188 , A61K31/424 , A61K31/429 , C07C311/29 , C07C311/46 , C07C2601/08 , C07C2602/10 , C07D213/64 , C07D213/643 , C07D215/14 , C07D215/227 , C07D215/233 , C07D217/18 , C07D235/12 , C07D239/34 , C07D239/60 , C07D261/14 , C07D263/22 , C07D263/58 , C07D277/64 , C07D277/68 , C07D295/096 , C07D295/192 , C07D307/79 , C07D307/80 , C07D307/82 , C07D307/84 , C07D319/18 , C07D321/10 , C07D333/20 , C07D333/36 , C07D333/66
摘要： The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.
摘要翻译： 本发明涉及治疗ADAMTS-5相关疾病，特别是骨关节炎的方法，其包括将能够将ADMATS-5活性调节至患有该疾病的受试者的药剂。 该试剂优选为联芳基磺酰胺化合物。 本发明部分地基于以下发现：与WT动物相比，不表达功能性ADAMTS-5的转基因动物在诱导骨关节炎之后表现出降低骨关节炎的程度。 此外，ADAMTS-5转基因动物与WT动物相比降低了关节组织中的聚集蛋白聚糖蛋白聚糖酶活性。 这些动物是ADAMTS-5相关疾病的良好模型，并且用于筛选可用于治疗和/或预防这些疾病的药物。 没有其他动物模型，其中单个基因的活性的缺失能够消除骨关节炎的过程。 因此，这些动物还显示可以通过向受试者施用ADAMTS-5抑制剂，特别是能够抑制ADAMTS-5的聚集蛋白聚糖酶活性的试剂来预防和/或治疗骨关节炎。
-
-
-
搜索结果
4 条记录 (耗时 0.023 秒)
